KR20260037107A - 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료 - Google Patents

재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료

Info

Publication number
KR20260037107A
KR20260037107A KR1020267002897A KR20267002897A KR20260037107A KR 20260037107 A KR20260037107 A KR 20260037107A KR 1020267002897 A KR1020267002897 A KR 1020267002897A KR 20267002897 A KR20267002897 A KR 20267002897A KR 20260037107 A KR20260037107 A KR 20260037107A
Authority
KR
South Korea
Prior art keywords
rvwf
vwf
infusion
von willebrand
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267002897A
Other languages
English (en)
Korean (ko)
Inventor
미란다 채프먼
브루스 에웬스타인
베티나 플로더
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20260037107A publication Critical patent/KR20260037107A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020267002897A 2017-07-07 2018-07-09 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료 Pending KR20260037107A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07
US62/530,027 2017-07-07
PCT/US2018/041320 WO2019010497A1 (en) 2017-07-07 2018-07-09 TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION
KR1020207003264A KR102921337B1 (ko) 2017-07-07 2018-07-09 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003264A Division KR102921337B1 (ko) 2017-07-07 2018-07-09 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료

Publications (1)

Publication Number Publication Date
KR20260037107A true KR20260037107A (ko) 2026-03-17

Family

ID=63036433

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267002897A Pending KR20260037107A (ko) 2017-07-07 2018-07-09 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료
KR1020207003264A Active KR102921337B1 (ko) 2017-07-07 2018-07-09 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207003264A Active KR102921337B1 (ko) 2017-07-07 2018-07-09 재조합 vwf의 투여에 의해 중증 폰 빌레브란트 병을 가지고 있는 환자에서 위장 출혈의 치료

Country Status (16)

Country Link
US (5) US10632176B2 (cg-RX-API-DMAC7.html)
EP (2) EP3648788B1 (cg-RX-API-DMAC7.html)
JP (2) JP7307047B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260037107A (cg-RX-API-DMAC7.html)
CN (1) CN111436193A (cg-RX-API-DMAC7.html)
AU (2) AU2018298233B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020000321A2 (cg-RX-API-DMAC7.html)
CA (1) CA3069295A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020001322A2 (cg-RX-API-DMAC7.html)
DK (1) DK3648788T3 (cg-RX-API-DMAC7.html)
ES (1) ES2986574T3 (cg-RX-API-DMAC7.html)
FI (1) FI3648788T5 (cg-RX-API-DMAC7.html)
MX (1) MX2025012580A (cg-RX-API-DMAC7.html)
PL (1) PL3648788T3 (cg-RX-API-DMAC7.html)
PT (1) PT3648788T (cg-RX-API-DMAC7.html)
WO (1) WO2019010497A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えvwfの投与による治療法
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
EA202192140A1 (ru) * 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
PL2167117T3 (pl) 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
US20110072524A1 (en) 2009-08-04 2011-03-24 Baxter International Inc. Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
EA202090067A3 (ru) 2010-07-08 2020-07-31 Баксалта Инкорпорейтид Способ получения рекомбинантного adamts13 в культуре клеток
CN103732244A (zh) 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää

Also Published As

Publication number Publication date
FI3648788T3 (fi) 2024-08-16
PT3648788T (pt) 2024-08-23
JP7307047B2 (ja) 2023-07-11
KR20200037235A (ko) 2020-04-08
PL3648788T3 (pl) 2024-10-07
US20230122958A1 (en) 2023-04-20
CA3069295A1 (en) 2019-01-10
US10632176B2 (en) 2020-04-28
EP3648788B1 (en) 2024-05-22
AU2025205392A1 (en) 2025-09-25
RU2020105682A3 (cg-RX-API-DMAC7.html) 2021-10-15
RU2020105682A (ru) 2021-08-10
JP2020526525A (ja) 2020-08-31
DK3648788T3 (da) 2024-08-19
JP7641327B2 (ja) 2025-03-06
US11529395B2 (en) 2022-12-20
US20190091299A1 (en) 2019-03-28
US20240316160A1 (en) 2024-09-26
BR112020000321A2 (pt) 2020-07-14
US12016904B2 (en) 2024-06-25
JP2023123738A (ja) 2023-09-05
EP3648788A1 (en) 2020-05-13
MX2025012580A (es) 2026-01-07
US20210169989A1 (en) 2021-06-10
US10905746B2 (en) 2021-02-02
ES2986574T3 (es) 2024-11-12
EP4424366A2 (en) 2024-09-04
US20200206318A1 (en) 2020-07-02
EP4424366A3 (en) 2024-12-04
AU2018298233A1 (en) 2020-01-30
WO2019010497A1 (en) 2019-01-10
CN111436193A (zh) 2020-07-21
KR102921337B1 (ko) 2026-02-02
AU2018298233B2 (en) 2025-04-24
CO2020001322A2 (es) 2020-02-18
FI3648788T5 (fi) 2024-09-09

Similar Documents

Publication Publication Date Title
JP7641327B2 (ja) 組換えvwfの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
KR20160091434A (ko) 재조합 vwf 제제
JP2025128168A (ja) 組換えVWF(rVWF)を使用する予防治療法
AU2025205070A1 (en) Treatment Of Patients With Severe Von Willebrand Disease Undergoing Elective Surgery By Administration Of Recombinant VWF
RU2844131C1 (ru) Лечение меноррагии у больных с тяжелой формой болезни фон виллебранда путем введения рекомбинтного vwf
RU2774720C2 (ru) ЛЕЧЕНИЕ ЖЕЛУДОЧНО-КИШЕЧНОГО КРОВОТЕЧЕНИЯ У ПАЦИЕНТОВ С ТЯЖЕЛОЙ ФОРМОЙ БОЛЕЗНИ ФОН ВИЛЛЕБРАНДА ПУТЕМ ВВЕДЕНИЯ РЕКОМБИНАНТНОГО ФфВ
RU2851973C2 (ru) Лечение пациентов с тяжелой формой болезни фон виллебранда, подвергающихся плановому хирургическому вмешательству, путем введения рекомбинантного ффв
HK40115617A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
CN115335074A (zh) 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
HK40029176A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
HK40029176B (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
HK40031159A (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)